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Abstract (WC=249) 
 
In an era of Precision Medicine it is vital to collect biological data within clinical trials and to 
integrate their analysis within the outcomes of the trial. The identification of genomic biomarkers 
that affect treatment response to smoking cessation treatment, both pharmacological and 
behavioral, or susceptibility to medication-related adverse reactions, holds real promise to 
improving treatment efficacy and to tailoring the treatment approach to the individual. However, 
a clear challenge in identifying reliable biomarkers is in obtaining adequate sample sizes. 
Consortium-based approaches will likely be necessary to yield real successes. Thus, meta-
analyses of data from individual smoking cessation trials will become crucial and will be 
facilitated by standardized trial designs, assessments, and outcomes, and harmonizable 
measures. To foster increased collection of high quality genetics data in clinical trials, we 
discuss 1) Genetically informed trial design, 2) Biological samples (collection requirements, 
storage, and analysis with a focus on genomic data) and genetics consortia, 3) Participant 
consent and data sharing requirements for Institutional Review Board (IRB) approvals, and 4) 
Information on phenotype characterization, and meta-analysis. This work aligns with the 
objectives of the Precision Medicine Initiative, and offers guidance for integrating treatment 
research and genetics/genomics within the nicotine and tobacco research community. It is 
intended to promote the collection and genotyping of biosamples in existing subject samples, as 
well as the integration of genetic research elements into future study designs. This paper cross-
references a companion paper in this issue that reviews current evidence on genetic and 
epigenetic markers in cessation trials. 
Keywords: Addiction, Cessation, Genetic Research, Treatment and intervention. 
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Implications 
This paper outlines a framework for the consistent integration of biological data/samples into 
smoking cessation pharmacotherapy trials, aligned with the objectives of the recently unveiled 
Precision Medicine Initiative. Our goal is to encourage and provide support for treatment 
researchers to consider biosample collection and genotyping their existing samples, as well as 
integrating genetic analyses into their study design in order to realize precision medicine in 
treatment of nicotine dependence. 
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1. INTRODUCTION 
Smoking is a major risk for preventable death and disability,1-4 and smoking cessation reduces 
the risk of mortality.5 However, cessation failure is common despite clinical practice guidelines6 
and available cessation medications, which are associated with different efficacies, side effects, 
adherence, use constraints, and costs.7 Cessation treatment, pharmacological or behavioral, 
may be improved via precision medicine: i.e., optimizing treatments to maximize efficacy and 
minimize side effects.8,9 Smokers vary greatly in the benefit they derive from particular 
pharmacotherapies, and biomarkers can predict a smoker’s response to a specific 
pharmacotherapy.10-14 Because the health cost of cessation failure is high, there is a need to 
identify treatments that are most likely to be effective for smokers who want to quit and to 
maintain long term abstinence.  
 
An important initiative of the NIH is to develop precision medicine to improve care.15 The 
initiative will increase our ability to characterize smokers and predict their responses to 
cessation pharmacotherapies. Such studies will help optimize treatments for enhanced efficacy 
and medication adherence, and to reduce side effects. In recent years, scientists have gained 
extensive knowledge on how personal factors (including genetics) can be used to predict 
important health outcomes.16 The concept of precision medicine is not new; clinical history of 
allergic reactions to medication, for instance, has been used to guide medication choice for 
more than a century.17 However, the assessment of individual variation has been dramatically 
improved by the recent development of large-scale biologic databases (i.e., the human genome 
sequence), and powerful methods for characterizing patients (i.e., proteomics, transcriptomics, 
epigenomics, metabolomics, and genomics). What is needed now is to leverage biological 
samples, test them rigorously, and ultimately use them to build the evidence-base needed to 
guide clinical practice. This will enable more accurate diagnoses, more rational disease 
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prevention strategies, better treatment selection, and the development of novel therapies, 
including ones for nicotine dependence and the multitude of tobacco-related diseases. 
 
The promise of precision medicine has already been fulfilled in some areas of medicine. For 
example, underlying causal genotypes are used to personalize cancer treatment.18  The 
application of genetic discoveries to clinical decision making and treatment decisions is 
occurring in a variety of medical specialties. For example, genetic screening has identified a 
specific molecular subset of non-small cell lung cancer patients, where patients positive for a 
specific oncogene were more likely to be young never-smokers or light smokers, compared to 
older, heavier smokers.19 In addition, guidelines from the College of American Pathologists and 
the International Association for the Study of Lung Cancer, recommend testing for two well-
characterized genetic biomarkers in patients newly diagnosed with non-small cell lung cancer: 
epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) for treatment 
guidance.20 The current clinical approach of using molecular and genetic phenotyping to guide 
clinical care of patients with lung cancer is a welcome addition to traditional therapy that has 
markedly limited effectiveness. In the field of addiction, genetic variants in the nicotinic receptor 
subunit gene CHRNA5, variants in the nicotine metabolism gene CYP2A6, and the nicotine 
metabolite ratio genotypes showed promise as a marker for smoking cessation 
pharmacotherapy selection. 21-25 
 
We are beginning to understand how to optimize therapies for other diseases based on different 
genetic polymorphisms.26,27 Thus, genetic variables are used to optimize drug selection and 
dosing;28  e.g., individual genetic profiles are used to avoid medications likely to cause serious 
adverse effects such as abacavir, carbamazepine and thiopurine.29-31 Finally, with individual 
whole genome or exome sequencing, we can now not only better classify diseases, but also 
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diagnose patients with previously undiagnosed genetic diseases.32,33 The Evaluation of 
Genomic Applications in Practice and Prevention34 Initiative, established by the National Ofﬁce 
of Public Health Genomics at the Centers for Disease Control and Prevention, supports the 
development and implementation of a rigorous, evidence-based process for evaluating genetic 
tests and other genomic applications for clinical and public health practice in the United 
States.34 
 
Based on the utility of individual biological variability for clinical care, we propose that, ideally, 
examination of biological samples should be integrated into clinical trials to address issues that 
are central to study aims, rather than as a data collection procedure merely affixed to the study. 
We encourage the next generation of scientists to develop creative new approaches for 
detecting, measuring, and analyzing a wide range of biomedical information including molecular, 
genomic, cellular, clinical, behavioral, physiological, and environmental parameters. The NIH’s 
Precision Medicine Initiative plans to recruit a longitudinal cohort of 1 million or more Americans 
to give consent for extensive characterization of biologic specimens (cell populations, proteins, 
metabolites, RNA, and DNA — including whole-genome sequencing, when costs permit) and 
behavioral data, all linked to their electronic health records as summarized in Figure 1.15 Blood 
specimens will be collected and processed using a standard CLIA compliant procedure, 
ensuring quality control and comparability, and sent to a local or central biorepository, that will 
support collection, processing, storage, retrieval and biochemical analysis and/or shipment to 
analytic laboratories, in addition to a wide range of phenotypic data including mobile health 
measures. Understanding the biological basis of complex traits will be informed by these 
technological advances in data generation from multiple levels of biological systems — including 
DNA sequencing,35 RNA expression,36,37 methylation patterns,38 other epigenetic markers,39 
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proteomics40 and metabolomics41 (see Figure 1). Corresponding actions are being undertaken 
in many other countries as part of their national genome strategies. 
 
Today, much treatment research is designed to develop and evaluate treatments that are 
expected to benefit the population as a whole, based on the expected response of a “typical” 
patient. However, individual patients can have markedly variable responses to therapy, ranging 
from highly efficacious outcome, to no effect, to deleterious outcome (see Figure 2). The roots 
of this variability likely include unrecognized differences in disease pathophysiology, 
environmental exposures, social and behavioral factors, and genetic factors. Prior research has, 
of course, used moderator variables to uncover person by treatment interactions. However, the 
new era will advance this effort via a much more precise and comprehensive assessment of 
individual biological characteristics. Thus, an important overarching goal is to determine whether 
and how state-of-the-art genomic biomarkers can be used to optimize smoking cessation 
pharmacotherapy to enhance efficacy and medication adherence, and to reduce side effects. 
 
To promote incorporation of genetics data into smoking cessation treatment research, in this 
review we discuss 1) study design considerations (e.g., genetically informed trial), 2) practical 
considerations of biological samples collection and participant consent for genetic data sharing 
requirements, 3) development of genetic consortia and meta-analysis to obtain adequate 
sample sizes for robust pharmacogenetics analyses, and 4) Information on phenotype 
characterization and outcome harmonization for cross-study comparisons. 
 
Key concepts and glossary 
This review seeks to inform a broad medical readership about the current status of how 
biological samples can be used in smoking cessation trials and to highlight the rationale, study 
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design, practical considerations, and opportunities for nicotine and tobacco researchers. Views 
are still evolving about several issues such as the clinical validity of potential genomic 
biomarkers. Current findings on biological markers for smoking cessation and a glossary for key 
genetic and “omic” terms are presented in a companion paper by Saccone et al.  
 
2. STUDY DESIGN CONSIDERATIONS AND EXAMPLES 
Here we present examples on how researchers can consider biosample collection and 
genotyping their existing samples, as well as integrating genetic analyses into their study 
design. Genetic data collection is easier compared to collection of therapeutic drug level or 
proteins, which may be more sensitive to temperature or light with more restrictive collection 
and storage procedures.  
 
A. Collecting biomarkers: Biomarkers relevant to nicotine and tobacco cessation research 
generally fall into three categories:42,43 (1) diagnostic biomarkers for patient selection; (2) 
pharmacodynamic biomarkers for optimal dosing; (3) predictive biomarkers for therapeutic 
efficacy, which may include pharmacodynamic (e.g.,genotypes at specific genetic variants, 
electroencephalogram or functional connectivity) and pharmacokinetic (e.g., nicotine metabolite 
ratio) biomarkers. Additional details on definitions of biomarkers and the Institute of Medicine’s 
proposed three-part framework for biomarker development (analytical validation, 
qualification/context of use and utilization)44 are described in more detail elsewhere.43  
 
Most biomarkers for omic research may be collected from whole blood or saliva. The timing of 
sample collection needs to be determined by the type and context of the research questions 
being addressed. For example, for germline DNA analyses, biosamples can be collected at any 
time prior to, during or after the study. However, gene expression and epigenetic studies are 
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often timed in relation to an exposure such as before and after drug administration or before and 
after smoking cessation, requiring careful adherence to the timing of a study’s primary endpoints 
in relevant tissue types. For example, some epigenetic markers are sensitive to smoking 
cessation and will revert to unexposed levels ranging from weeks to years after smoking 
cessation depending on specific markers. 45-47 Consent forms should be thorough and specific 
enough to include whatever type of biomarkers one intends to collect. Furthermore, informed 
consent documents would need to be modified any time a novel omic test is added to an extant 
research plan. Trained phlebotomists, who could be research assistants, that receive special 
training and meet CLIA-requirements, should collect whole blood samples. Saliva sample 
collection can be easily performed by study participants according to manufacturer’s protocols 
and clear participant instructions.  
 
For DNA collection, saliva sample collection can be performed feasibly by mail using pre-
addressed, return envelopes and collection kits available from multiple manufacturers.48,49 In 
contrast, collection of other omics data may be more restrictive such that all samples should be 
frozen in -80°C or colder freezers as rapidly as possible after collection in appropriate 
containers to maintain the specific omic features. Investigators designing a biomarker study 
without previous experience can often contact their institutions’ IRB for standard language 
required for informed consent documents and contact experienced investigators for sample 
collection, storage and processing protocols. We have also provided template language in 
Supplementary Table 1. 
  
B. Biomarker-based randomization: There are at least three general types of randomized 
controlled trial (RCT) designs for pharmacogenomic investigations of smoking cessation, as 
illustrated in Figure 3 – according to a presentation by Dr. Caryn Lerman at an Institute of 
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Medicine Roundtable on Translating Genomic-Based Research meeting on evidence generation 
for genomic diagnostic test development.50 Most pharmacogenetics studies of smoking 
cessation are analyses of genetic data from existing treatment studies (e.g., a single 
polymorphism, multiple polymorphisms, additive genetic risk scores or metabolite proxies for 
polymorphisms), and is called a Retrospective design. That is, analyses are conducted after 
completion of the RCT that relate patient biological variables such as genotype or metabolite 
status (e.g., normal vs. slow nicotine metabolizers) to targeted clinical outcomes: e.g., efficacy 
of the drug for smoking cessation or the reduction of nicotine withdrawal symptoms, smoking 
urges, drug dosing, or side effects (Figure 3). Retrospective trials are useful when the clinical 
utility of such markers is unknown or not well established at the time of trial initiation and can 
inform hypothesis generation, replication and independent validation. Retrospective designs 
have several limitations, such as unbalanced groups (status on a biomarker might be unevenly 
distributed across groups), reduced power resulting from either unbalanced groups or highly 
skewed biomarker distributions due to base rates of the biomarker status,  and missing data 
because not all patients consented to provide biosamples. 
 
Prospective pharmacogenomic trials can be divided into two types: prospective stratified and 
prospective screened.50 Prospective stratified trials conduct testing of a biomarker prior to trial 
entry and define a biomarker as ‘positive’ or ‘negative’. An advantage of this design is that the 
trial is hypothesis-driven, taking into account prior knowledge about a biomarker and members 
of the test population. Another advantage of this design is that it permits enrichment of the less 
common genotype or biomarker by oversampling during the screening process – in order to 
achieve balanced groups. For example, Lerman and colleagues tested smokers for the nicotine 
metabolite ratio (NMR; 3ʹ-hydroxycotinine/cotinine) and set an initial cut-off based upon prior 
knowledge51 to define ‘normal metabolizers’ and ‘slow metabolizers’.52 Marker positive and 
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marker negative smokers were then independently randomized to either nicotine replacement 
patch or placebo patch or varenicline, resulting in balanced groups by biomarker status and 
drug. Roughly 20% of patients, depending on ancestry, were slow metabolizers. Thus, 
oversampling of slow metabolizers was required in this prospective stratified study and resulted 
in excluding many patients who tested positive for normal metabolizer status. In another 
ongoing study by Chen and colleagues, participants receive prospectively stratified treatment 
randomization by the individual’s cessation-relevant genotypes such as the CHRNA5 D398N 
gene variant 21,23 in order to yield balanced groups for testing the relation of genotype status 
with medication efficacy and adverse effects. 22 
 
A third type of pharmacogenomic trial is the prospective screened design in which patients are 
randomized to receive biomarker-guided treatment or usual care. In the biomarker-guided 
treatment group, patients are tested for genotype or metabolite status and assigned to a 
treatment based on a hypothesized association of the marker with the efficacy of a particular 
drug (Figure 3). Assume for example that genotype AA (marker positive) for a given 
polymorphism predicts enhanced efficacy of nicotine replacement therapy (NRT), but not 
varenicline efficacy.  Genotype GG (marker negative) on the other hand, predicts enhanced 
efficacy of varenicline, but not NRT efficacy. Therefore, in the genotype-guided group patients 
with genotype AA would receive NRT and patients with genotype GG would receive varenicline. 
Patients in the usual care group would receive either a pre-defined standard medication, or they 
might be randomized to either of the drugs, or their physician might prescribe their medication 
based on usual practice. The results of the genotype-guided group would then be compared 
with the usual care (non-guided) group. An advantage of the prospective screened design is its 
potential for high ecological validity, offering evidence of whether or not a genotype- or 
metabolite-driven therapy provides improved effectiveness over non-guided therapy in non-
12 
 
 
research settings.50  
 
In addition to these three general designs for pharmacogenomics RCTs, other designs are more 
fitting for enabling clinical implementation and patient-centered effectiveness, such as pragmatic 
trial designs that evaluate metrics germane to real-world clinical practice such as cost-
effectiveness, patient satisfaction, clinical outcomes and feasibility.50,53,54 In addition, it may be 
advantageous for researchers to use factorial designs to explore pharmacogenetic relations. 
This is, in part, because of the efficiency of such designs, as they permit experimental analysis 
of multiple, discrete intervention components.55,56 Thus, the researcher might investigate the 
efficacies of both multiple pharmacotherapies, and at different levels of counseling intensities. 
Another advantage of such designs is that they provide relatively good power; when each factor 
comprises two levels, all subjects in the design contribute to estimation of the effects of each 
factor.  Also, they uniquely permit estimation of interaction effects. For instance, they might 
reveal that genetically determined differential response to a medication might be neutralized by 
more intense counseling, or by the conjoint use of two medications. For more details about trial 
design, we refer readers to these reports.43,50,55,56 
 
3. PRACTICAL CONSIDERATIONS 
The benefits and challenges of various biosampling options regarding biospecimen 
requirements, storage and analysis are summarized in Table 1. 
 
Collection of appropriate participant consent 
Collection of informed written consent from participants to use their biological samples for the 
purposes of genetics testing is critical to the ethical conduct of genetics research. Research 
participants need to know what data will be studied, who will have access to their genetics data, 
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what protection will be in place to ensure the anonymity of their genetic information is 
maintained, and any other study-specific information. 
 
For some clinical trials it may be necessary for the genetic testing to be a mandatory component 
of participation in the research. If this is the case, then consent for genetic testing should be 
included as part of the informed consent for the study as a whole. However for some studies, 
participating in the genetics part is not essential. In this case, the genetics part of the research 
can be presented to the participant as an optional ‘sub-study’, and a separate informed written 
consent specifically for genetic or other omics participation should be completed. In our 
experience, majority of participants consent to give biological samples (e.g. blood or saliva) for 
genetic studies 57, whether these results can generalized to individuals who decline biological 
samples needs to be examined in future research.  
 
Participants must be advised of the potential privacy risks associated with donating a DNA 
sample for research. The consent form should provide instruction to participants regarding the 
importance of actively protecting their own privacy. Participants should be informed about the 
Genetic Information Nondiscrimination Act (GINA), which makes it illegal for health insurance 
companies, group health plans, and most employers to discriminate against people based on 
their genetic information. The consent form should also describe the protections taken by the 
study to protect the privacy of participants. These may include assignment of unique numerical 
identifiers that are used to label all samples and genotypic data, procedures for securely storing 
hard copy records and electronic data, and attainment of a Certificate of Confidentiality from the 
Department of Health and Human Services. Supplementary Table 1 provides research elements 
and example consent languages for study purpose, risks/benefits, confidentiality, sample and 
information on storage and destruction. We acknowledge that there are clinical trial situations in 
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which collection of biosamples may not be feasible due to specific concerns (e.g., certain 
vulnerable population, costs)  
 
NIDA Genetics Consortium (NGC), NIDA Genetics Study Center (Biorepository), and NIH 
Resource Sharing Guidelines 
As described earlier, consortium-based biorepositories are important to enable evidence 
needed for translation. The NIDA Genetics Consortium was created in 1999 to identify human 
genes for drug addiction, create a repository of data, generate a database on genetics of drug 
use and related phenotypes, and establish a consortium of collaborating scientists.58 In 
particular, the NIDA Center for Genetics Studies (NCGS Biorepository) is a NIDA-funded 
scientific resource for informing the human molecular genetics of addiction. The Biorepository 
will produce, store, and distribute clinical data and biomaterials (DNA samples and cell lines) 
available in the NIDA Genetics Initiative.58 The Biorepository collects high-quality DNA, plasma 
(if consented), and cryopreserved lymphocytes (CPLs) on all whole blood samples submitted by 
NGC members. The sharing of data in the NCGS is done in strict accordance with the informed 
consent provided for each research subject. Many genotyping arrays are available including a 
NIDA-funded custom genotyping array for studying the genetics of addiction and treatment.59 
 
Support outside of United States 
Most high-income countries in Europe and elsewhere in the world have equivalent ethical and 
data protection procedures and legislation as in the U.S., but details vary. European data 
protection regulations are more restrictive than in the U. S., and genetic study data are typically 
deposited at the European Bioinformatics Institute (EMBL-EBI) (www.ebi.ac.uk). Clinicians 
planning to undertake such studies outside the U.S. should refer to national ethics boards and 
data protection agencies for guidance as needed. 
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4. META-ANALYSIS AND HARMONIZATION 
The research is growing on treatment effect in the context of differences in participants, clinical 
trial designs and treatments using systematic reviews, traditional meta-analyses and more 
recent methods such as Bayesian, multiple treatment, multiple outcome, and network meta-
analysis. Clinical and statistical experts have estimated effect sizes of participant, clinician, and 
treatment factors on prospective abstinence using meta-analyses of randomized clinical trials of 
smoking cessation.6,60 Meta-analysis goals include utilization of the retrospective evidence base 
(e.g. based on published literature) to (1)  provide guidance to patients and clinicians,61 (2) 
evaluate effect modification, e.g., of nicotine dependence62 or genetic variants,21 on outcomes, 
and (3) develop clinical trial hypotheses for design and analysis.63  In addition, de novo 
collaborative meta-analyses, which utilize new analyses of existing data, usually with 
harmonized phenotypes and uniform analytic models, have been highly effective in aggregating 
evidence for human genetic associations, including for smoking behavioral traits.64-67 
 
Development of databases for pursuing meta-analysis of smoking cessation clinical trials 
involves identifying participant, treatment, and outcome measures from existing RCT datasets, 
comparing assessments used to obtain these data, and reviewing coding. Harmonization 
approaches to render clinical trials suitable for data analysis include expert opinion, regression 
analyses, and multiple imputation methods. The degree of harmonization between phenotypes 
in two clinical trials can be assessed if at least one of those trials contains all the information 
required to estimate the phenotype in the other trial. The degree of agreement between those 
phenotype estimates is a measure of harmonization. Multiple imputation is applicable to target 
phenotypes that are missing by design, i.e., that can be considered to be missing completely at 
random; when missing values are not missing at random, the resulting imputation of the target 
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phenotype might be biased. This situation may arise for abstinence when the subject fails to 
report abstinence because they have relapsed. The usual approach is to assume that all non-
reporting individuals have relapsed. However, this approach ignores the accessible factors that 
are related to missing data and the outcome. In such cases, it may be better to apply a 
principled method to account for the effects of the accessible mechanism.68,69 Harmonization of 
prospective abstinence outcome measures has been discussed by clinical experts.70  Interval-
censored regression is an indirect method of harmonization applicable if response categories 
differ for a group of phenotypes that are otherwise consistently measured. On the other hand, 
pharmacogenomic allele nomenclature standardization (to human reference sequence 
assemblies) contributes to the ongoing nicotine metabolism biomarker and genotype metric 
harmonization efforts.71 
 
Multiple treatment comparison meta-analysis is a form of integrated data analysis that includes 
the more familiar meta- and mega- analysis approaches and enables both direct and indirect 
comparisons of treatment effects.63,72 Direct comparisons of treatment effects take place when 
individuals are randomized to different treatments; indirect comparisons of treatment effects 
take place when analyses rely upon multiple direct comparisons to estimate the indirect 
comparison via a network. Analysis of both direct and indirect treatment effect comparisons 
increase the total sample size of the treatment comparisons and may, as in conventional meta-
analyses, identify heterogeneity between randomization arms, or between directly and indirectly 
estimated effects. Examination of modeling assumptions through simulation, sensitivity analyses 
and collaborative standardized approaches will be necessary to integrate multiple related 
patient and environmental information and extract guidance from analyses of clinical trials.  
 
5. INFORMATION ON PHENOTYPE ASSESSMENT AND CHARACTERIZATION 
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Phenotype Assessment 
The key conceptual and practical considerations for phenotyping overlap considerably with 
issues surrounding assessment of treatment efficacy. Thus, existing conventions established to 
promote the rigor and comparability of smoking cessation studies also provide useful guidance 
for phenotype assessment.70,73 
 
A common primary endpoint for cessation studies is the attainment of an extended period of 
abstinence from smoking at a distal follow-up after the quit date (typically 6 or 12 months). 
Individuals who meet these benchmarks remain at risk for relapse,74 however a lengthy period 
of sustained abstinence is the best available indicator of lifelong abstinence, the typical 
treatment goal and the outcome expected to yield the maximal health benefit. The SRNT 
workgroup on outcomes in clinical trials recommended using a “prolonged abstinence” standard, 
defined as a period of sustained abstinence following a short (i.e., 2 wk) initial grace period,70 
with point prevalence of 7-day abstinence as a secondary measure. A proposed alternative, the 
“Russell Standard Abstinence” definition, requires the conjunction of a self-report of smoking 5 
or fewer cigarettes since the quit date and a negative biochemical test at the follow-up.73 Both 
definitions incorporate allowances for a limited amount of smoking after the target quit date, 
recognizing that smoking cessation is a difficult process and temporary setbacks do not 
necessarily preclude long-term success, and that treatment delivery generally continues beyond 
the quit date. However, the various definitions are differentially sensitive to post-quit lapsing that 
occurs relatively late in the follow-up period, but that still may be effectively treated by continued 
treatment.75 In essence, the researcher must try to adopt an outcome definition that is clinically 
meaningful, mergeable across other studies, and that provides a sensitive signal of targeted 
treatment effects.  
18 
 
 
 
These conventions provide important information about ultimate clinical outcomes, but they offer 
little insight into the process of cessation or the mechanisms through which treatments exert 
their effects. One complementary approach is to focus on pivotal clinical milestones in the 
cessation process, such as the establishment of an initial period of abstinence, the occurrence 
of the first smoking lapse, and the transition from a lapse to full relapse.76 In treatment 
evaluation research, a series of survival analyses can be used to test whether treatment 
condition influences the time to each milestone, providing clues as to how effective treatments 
work.76,77 An assumption here is that these milestones are differentially sensitive to medication 
effects and their relations with omic determinants. For instance, there is some evidence that the 
effects of medication early in the quit attempt (e.g., on initial abstinence) are especially sensitive 
to medication benefit.55,64,78 
 
Another fruitful approach is to measure presumed mediators of treatment effects.78,79 The most 
relevant mediators can differ as a function of the treatment being evaluated, but a host of 
common barriers to cessation have been identified by theory and empirical investigations of 
lapse antecedents. These include urge/craving, withdrawal symptoms, exposure to tobacco 
cues, stressors, alcohol use, and reactions to lapse events80,81 In pharmacotherapy studies, 
medication compliance and drug side effects may represent important mediators of treatment 
outcome.82,83 Investigating whether treatment allocation influences these barriers to cessation, 
and testing whether group differences in long-term outcomes are mediated through effects in 
these domains, can help to refine our understanding of treatment mechanisms. There is also the 
prospect that medication effects on sensitive mediators (e.g., craving suppression) provide 
especially sensitive indices of medication benefit.84 
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Genetic studies of smoking cessation will benefit from incorporating clinical phenotypes rooted 
in each of these approaches. Long-term abstinence endpoints seem strongly indicative of the 
public health benefit of treatment, and thus clearly relevant to the development of precision 
medicine protocols. Investigating how candidate genetic markers influence clinical milestones 
and treatment mediators in addition to the traditional outcome of end of treatment abstinence 
may lead to a better understanding of their functional significance (e.g., due to differential 
contribution of error).78,85  Use of multiple outcomes may be especially valuable for positional 
candidates discovered via genome-wide scans that are not anticipated by theory and for which 
knowledge of biological function is lacking. On the other hand, increasing biological knowledge 
in genomic databases speeds the discovery process to link genes, functions, and clinical 
outcomes. Of note, is that, the causal gene and variants are not necessarily the ones closest to 
the genetic marker identified in a genome-wide screen. 
 
Anticipation of genetic analyses may encourage investigators to alter their assessment plans 
when designing cessation trials. Pooling or meta-analyzing data from many trials represents a 
powerful method for exploring genetic influences on smoking cessation. This encourages the 
use of broad and flexible assessment strategies. Ideally, clinical studies would incorporate 
detailed assessments of smoking behavior with good resolution of timing, amount, antecedents, 
and consequences of post-cessation cigarette use. Examples include calendar-based methods 
or intensive longitudinal assessments.86,87 This would allow outcomes to be scored according to 
multiple criteria (e.g. various grace periods or thresholds for progression to the relapse 
milestone), facilitating cross-trial harmonization and pooled analyses.  
 
When designing a stand-alone trial, it may make sense to assess a small set of targeted 
mediators based on a working knowledge of the treatment under study, i.e., how the tested 
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treatment is thought to work. However, the possibility of future, pooled genetic analyses should 
encourage clinical investigators to cast a wider net when it comes to assessing possible 
mediators. This alternative approach is to assess mediators based on the outcome model – 
what important factors may influence outcomes. One reason is that there is often uncertainty 
about which genetic variant(s) may eventually be tested in secondary analyses, and therefore 
the important mediator(s) may not be knowable in the trial-planning phase. A second 
consideration is that mediators thought to be irrelevant in an individual trial might be very 
important in a pooled or aggregated analysis. 
 
Increasing need for interdisciplinary collaboration and data sharing has led to initiatives such as 
the PhenX Toolkit88 and the PROMIS system89,90 designed to encourage use of consensus 
measures in health research. Going forward, the smoking cessation field might benefit from 
development and dissemination of a comparable set of standardized, flexible assessment tools 
designed to gather information on post-cessation smoking patterns, common barriers to 
cessation, variables that may mediate of treatment effects, and potentially useful intermediate 
phenotypes for genetic research.  
 
6. CONCLUSION 
In the era of ‘Precision Medicine’, it is becoming increasingly important that investigators collect 
biological samples within clinical trials and integrate their analysis and interpretation with the 
goals of the trial. The identification of genomic markers that affect response to smoking 
cessation pharmacotherapies, or susceptibility to adverse reactions to such drugs, holds real 
promise to improve smoking cessation treatment efficacy through tailored treatment 
interventions, pharmacological or behavioral. A major concern for trial design is the timing of 
genomic assessment. Available genomic data before treatment randomization will allow gene-
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based stratified randomization or experimental testing of gene-based personalized treatment, 
while collection of any biosamples at any time in the trial for subsequent genotyping is still 
beneficial. Another challenge in identifying such genomic biomarkers will be to obtain adequate 
sample sizes. Consortium-based approaches will likely be necessary to yield real successes, as 
we have seen from previous genome-wide association studies of complex traits including 
smoking behavior.64-66,91-93 Thus for pharmacogenomic studies, meta-analysis of data from 
individual smoking cessation trials will be crucial and will require comparable trial designs and 
outcomes.21,94,95 Other related topics such as the genetic effects on smoker response to non-
pharmacologic smoking cessation interventions are not included in this review. 
 
In this paper, we outline a framework for the consistent integration of biological data/samples 
into smoking cessation pharmacotherapy trials. This work aligns with the objectives of the 
recently unveiled Precision Medicine Initiative, and addresses a call for practical advice to guide 
the integration of treatment and genetics research within the nicotine and tobacco research 
community. Our goal is to encourage treatment researchers to consider biosample collection 
and genotyping their existing samples, as well as integrating genetic analyses into their study 
design. Of course, identifying an optimal pharmacogenetic strategy is highly complex, as 
treatment trials vary in study designs, the type and intensity of the counseling treatment 
provided to all groups including the placebo arm, subject inclusion/exclusion criteria, and other 
experimental methods. Still, progress is underway, as reviewed in the companion paper by 
Saccone et al.  In summary, this work encourages and provides support for study designs that 
are needed in order to realize precision medicine in treatment of nicotine dependence.96 
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Figure Legend:  
 
Figure 1.  
Title: Biological systems multi-omics from the genome, epigenome, transcriptome, proteome 
and metabolome to the phenome 
Legend: single-nucleotide polymorphism (SNP), copy number variation (CNV), micro RNA 
(miRNA). 
 
Figure 2.  
Title: Example: Benefits of nicotine replacement therapy may vary by genetic marker 
Legend: 
Blue: patients who benefit; Clear: patients who fail to benefit,21,97 both studies of European 
Ancestry. 
 
Figure 3.  
Title: Pharmacogenomic trial designs, including retrospective, prospective stratified, and 
prospective screened. Source: Adapted from Lerman, IOM workshop presentation on November 
17, 2010 
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Table 1. Pros and Cons of Biological Samples 
 
Type of 
biosample 
Primary Use Storage Pros Cons 
Whole blood Generate 
subfractions 
[plasma, serum 
and cells (for 
extraction, viable 
storage, or 
transformation)], 
and isolate nucleic 
acids, proteins, 
and metabolites. 
Ultra-low 
temperature with 
some alternative 
storage 
approaches. 
Wide variety of 
fractions and 
analytes.  
Costs proportional 
to the 
number/diversity of 
tubes drawn and 
subsequent 
processing steps. 
Requires access 
to -80C freezer. 
Need access to 
phlebotomist 
 
Saliva Isolate nucleic 
acids and proteins 
from host and from 
the meta-genome. 
Room temperature 
for saliva possible; 
ultra-low 
temperature for 
analytes. 
Ease of collection. 
Can be done 
remotely and 
mailed in. 
Lack of clinical 
observation during 
collection results in 
minor rate of 
biospecimen 
substitution. 
Quality/quantity of 
DNA lower than for 
blood. 
Contamination of 
DNA from food 
etc. 
Urine Isolate 
metabolites. 
Ultra-low 
temperature. 
24 hour urine 
collection is 
standard but 
processing urine 
volumes can be 
challenging. 
Requires access 
to -80C freezer. 
No DNA. 
Buccal Cells Isolate nucleic 
acids 
Ultra-low 
temperature. 
One tissue type 
exposed to the 
environment highly 
relevant to 
smoking/vaping 
behaviors. 
Care in selecting 
buccal sampling 
protocol for 
comparability. 
 
